Key Takeaways
- ARK Invest divested 182,767 shares of Strata Critical Medical (SRTA) through two ETFs on April 13, 2026, totaling approximately $738,378
- This represents a continued divestment strategy, following ARK’s sale of more than 75,000 shares on April 10
- Strata Critical Medical operates a specialized healthcare logistics platform serving the organ transplantation industry nationwide
- Wall Street analysts from two major firms launched coverage with Buy recommendations and $8 price targets
- Consensus analyst projections indicate a price target of $9.08, representing potential gains exceeding 120% from the current $4.12 trading level
Cathie Wood’s investment firm, ARK Invest, has been methodically reducing its holdings in Strata Critical Medical throughout recent trading sessions. On April 13, 2026, the firm liquidated 182,767 shares across two of its exchange-traded funds—the ARK Autonomous Technology & Robotics ETF and the ARK Space Exploration & Innovation ETF. The transaction value reached approximately $738,378.
Strata Critical Medical, Inc., SRTA
This divestment appears strategic rather than isolated. Earlier in the week, on April 10, ARK offloaded over 75,000 shares, and the fund has executed multiple sales throughout this timeframe. The recurring nature of these transactions suggests a calculated shift away from the healthcare logistics company.
Strata Critical Medical operates as a specialized small-cap entity within the healthcare logistics sector. The company manages what it describes as the nation’s most extensive air transportation and surgical support infrastructure dedicated to organ transplant facilities. According to the company, it represents the sole comprehensive solution provider for organ transplant logistics across the entire process.
Currently, SRTA shares trade near the $4.12 mark. The stock experienced a 2% uptick on April 13 and has delivered a 51% return over the trailing twelve months, positioning it within penny stock classification.
Wall Street Remains Optimistic Amid ARK’s Retreat
While ARK continues its exit strategy, a pair of prominent Wall Street analysts have recently launched coverage with constructive outlooks.
Yuan Zhi from B. Riley initiated coverage assigning a Buy rating alongside an $8 price objective. Zhi highlighted the company’s dominant positioning within the U.S. organ transplantation sector and emphasized its unique status as the sole comprehensive logistics solution provider in this specialized market.
Similarly, Craig-Hallum’s Bill Bonello established coverage with a Buy rating and identical $8 target price. Bonello noted that despite significant operational improvements implemented over the past twelve months, the market has yet to properly value these transformations in the current share price.
Both analysts anticipate that investor sentiment will strengthen as the company delivers greater financial transparency and execution visibility.
Analyst Consensus and Price Projections
According to TipRanks data, Strata Critical Medical maintains a Strong Buy consensus rating supported by three unanimous Buy recommendations from covering analysts.
The mean price target among analysts stands at $9.08, indicating potential appreciation exceeding 120% relative to the current trading price near $4.12.
Bonello further noted that existing Street estimates may actually underestimate the company’s potential, indicating that actual performance could exceed current projections and provide even greater upside than models currently suggest.
ARK Invest has not issued any public commentary explaining the rationale behind its ongoing share liquidation, and no offsetting purchase activity was documented on April 13.
Strata Critical Medical closed trading at $4.12 on April 13, 2026, with three Buy-rated analysts on record and a consensus price target of $9.08.
